Navigation Links
Amyris Biotechnologies Announces $70 Million Series B Round
Date:9/19/2007

Prominent Investors Include DAG Ventures, Khosla Ventures, Kleiner Perkins

Caufield & Byers, and TPG Ventures Strong Endorsement of Technology Pioneer at Forefront of Developing No-

Compromise Biofuels

EMERYVILLE, Calif., Sept. 19 /PRNewswire/ -- Amyris Biotechnologies, an innovator in the development of renewable hydrocarbon biofuels, today announced that it closed the first tranche of its $70 million Series B funding. Duff Ackerman & Goodrich Ventures (DAG Ventures) led the financing and was joined by existing Series A investors, including Khosla Ventures, Kleiner Perkins Caufield & Byers, and TPG Ventures. The Series B funding will be used to further the development and scale up of its technology for the production of three transportation biofuels: bio-gasoline, bio-diesel, and bio-jet, and to support business initiatives to enable Amyris to bring its biofuels to market as early as 2010.

"Amyris has not only a break-through technology but a clearly defined strategy to commercialize a promising slate of next-generation biofuels that could have a profound impact on the transportation market," said R. Thomas Goodrich at DAG Ventures. "We are investing with strong confidence in what Amyris is creating as well as the management and scientific team the company is putting in place to execute on its vision."

"No-compromise transportation fuels derived from renewable sources hold substantial promise for meeting the tremendous need for alternative energy sources in the future," said John Melo, CEO of Amyris. "We have already succeeded in creating these biofuels in our lab. We are delighted with the strong interest in our Series B funding which will enable us to continue the research and scale-up of our technology and to implement our business model as the first biofuels company to go from production to customer."

Amyris pioneered a unique technology platform that allows it to use a variety of environmentally-friendly renewable feedstocks including sugarcane, corn and cellulose, to produce high-value compounds. This technology has been proven in Amyris' earlier non-profit project, funded through a grant to the Institute for One World Health from the Bill and Melinda Gates Foundation, to reduce the production cost of artemisinin-based anti-malarial drugs. Using the same technology platform, Amyris is now developing capabilities to produce a slate of high-performing hydrocarbon transportation biofuels that are environmentally friendly, cost- effective, and compatible with current engines and distribution infrastructure.

"Amyris is designing better biofuels from designer bugs," said John Doerr, partner at Kleiner Perkins Caufield & Byers. "This is a big deal because Amyris' cost competitive biofuels will work with existing engines without compromising performance and will have a lower carbon footprint. This financing will help Amyris scale with speed."

Amyris expects to close the second tranche of its Series B financing by the end of 2007.

About Amyris Biotechnologies

Amyris Biotechnologies (http://www.amyrisbiotech.com) is applying its proprietary, breakthrough technology to address major global health and energy challenges. Amyris' technology is used to produce high-value compounds to enable the production of lower cost artemisinin-based anti-malarial drugs and a slate of renewable hydrocarbon biofuels which are expected to be cost-effective and compatible with existing engines and distribution infrastructure. Based in Emeryville, CA, Amyris is a privately-held venture backed company whose investors include DAG Ventures, Khosla Ventures, Kleiner Perkins Caufield & Byers and TPG Ventures.


'/>"/>
SOURCE Amyris Biotechnologies
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... and solutions to the healthcare market. The company's primary focus is on new ... and marketing strategies that are necessary to help companies efficiently bring their products ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):